TF and cancer: Later, TF was also validated as a target in other cancer indications in others works investigating antibody–drug conjugates (ADC) against TF [100,101,102] and in our own work of chimeric antigen receptor-modified NK (CAR-NK) cell therapy [103] under preclinical and clinical investigations.